Meiji Holdings Co Ltd
SWB:3M0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Meiji Holdings Co Ltd
SWB:3M0
|
JP |
|
Heineken Holding NV
OTC:HKHHY
|
NL |
|
UPM-Kymmene Oyj
OMXH:UPM
|
FI |
|
G
|
Glencore PLC
SWB:8GC
|
CH |
|
S
|
Swiss Life Holding AG
XBER:SLW
|
CH |
|
F
|
FirstEnergy Corp
XBER:FE7
|
US |
|
Aytu Biopharma Inc
NASDAQ:AYTU
|
US |
|
P
|
Principal Financial Group Inc
DUS:PG4
|
US |
|
Rollins Inc
NYSE:ROL
|
US |
|
V
|
Veolia Environnement SA
XBER:VVDH
|
FR |
|
Ontex Group NV
OTC:ONXYY
|
BE |
Meiji Holdings Co Ltd
Meiji Holdings is a Japanese company that makes branded foods and medicines. Its food business includes milk, yogurt, cheese, ice cream, chocolate, candy, and other packaged foods sold under the Meiji name. Its pharmaceutical business develops and sells prescription drugs, including treatments used in hospitals and clinics. The company sells mainly to everyday consumers through supermarkets, convenience stores, and other retailers, and to healthcare providers through drug distributors, hospitals, and pharmacies. It makes money by manufacturing products and selling them through those channels, with recurring demand coming from household food purchases and from medical treatment needs. What makes Meiji’s business model distinct is that it combines a stable consumer foods business with a healthcare business. That gives the company two different revenue engines: one tied to daily eating habits and brand loyalty, and another tied to medicine use and the healthcare system. This mix helps Meiji play a broad role in Japan’s food and pharmaceutical supply chains.
Meiji Holdings is a Japanese company that makes branded foods and medicines. Its food business includes milk, yogurt, cheese, ice cream, chocolate, candy, and other packaged foods sold under the Meiji name. Its pharmaceutical business develops and sells prescription drugs, including treatments used in hospitals and clinics.
The company sells mainly to everyday consumers through supermarkets, convenience stores, and other retailers, and to healthcare providers through drug distributors, hospitals, and pharmacies. It makes money by manufacturing products and selling them through those channels, with recurring demand coming from household food purchases and from medical treatment needs.
What makes Meiji’s business model distinct is that it combines a stable consumer foods business with a healthcare business. That gives the company two different revenue engines: one tied to daily eating habits and brand loyalty, and another tied to medicine use and the healthcare system. This mix helps Meiji play a broad role in Japan’s food and pharmaceutical supply chains.
Operating Profit Beat: First-half operating profit reached JPY 40.9 billion, beating the company plan of JPY 39.5 billion, mainly on strong Pharmaceuticals performance.
Net Sales Softness: First-half consolidated net sales were JPY 574.8 billion, up 1.0% year-on-year but below initial plan, prompting a slight downward revision to full-year sales guidance.
Net Profit Decline: Net profit for the first half was JPY 21.4 billion, down 20.1% year-on-year, missing plan by JPY 1 billion due to tax and minority interest impacts.
Unchanged Profit Guidance: Despite lower sales outlook, full-year operating profit and net income guidance remain unchanged.
Cost & Pricing Actions: Price increases and cost management are helping offset higher raw material and logistics costs, with further structural reforms underway.
Segment Highlights: Food profit is growing despite mixed product performance; Pharmaceuticals saw strong vaccine results, but major antibiotics lagged.
China Strategy: The company is reviewing its overseas food strategy, with a focus on improving performance and allocating resources to stronger confectionery businesses.
